Cargando…
PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429176/ http://dx.doi.org/10.1097/01.HS9.0000851756.51961.79 |
| _version_ | 1784779356106653696 |
|---|---|
| author | Lal, A. Brown, R. C. Coates, T. Kalfa, T. Kwiatkowski, J. Brevard, J. Trenor, C. Wood, K. Sheth, S. |
| author_facet | Lal, A. Brown, R. C. Coates, T. Kalfa, T. Kwiatkowski, J. Brevard, J. Trenor, C. Wood, K. Sheth, S. |
| author_sort | Lal, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429176 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94291762022-08-31 PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE Lal, A. Brown, R. C. Coates, T. Kalfa, T. Kwiatkowski, J. Brevard, J. Trenor, C. Wood, K. Sheth, S. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429176/ http://dx.doi.org/10.1097/01.HS9.0000851756.51961.79 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Lal, A. Brown, R. C. Coates, T. Kalfa, T. Kwiatkowski, J. Brevard, J. Trenor, C. Wood, K. Sheth, S. PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE |
| title | PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE |
| title_full | PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE |
| title_fullStr | PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE |
| title_full_unstemmed | PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE |
| title_short | PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE |
| title_sort | pb2232: trial in progress: a phase 2, open-label study evaluating the safety and efficacy of the erythrocyte pyruvate kinase activator etavopivat in patients with thalassemia or sickle cell disease |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429176/ http://dx.doi.org/10.1097/01.HS9.0000851756.51961.79 |
| work_keys_str_mv | AT lala pb2232trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyoftheerythrocytepyruvatekinaseactivatoretavopivatinpatientswiththalassemiaorsicklecelldisease AT brownrc pb2232trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyoftheerythrocytepyruvatekinaseactivatoretavopivatinpatientswiththalassemiaorsicklecelldisease AT coatest pb2232trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyoftheerythrocytepyruvatekinaseactivatoretavopivatinpatientswiththalassemiaorsicklecelldisease AT kalfat pb2232trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyoftheerythrocytepyruvatekinaseactivatoretavopivatinpatientswiththalassemiaorsicklecelldisease AT kwiatkowskij pb2232trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyoftheerythrocytepyruvatekinaseactivatoretavopivatinpatientswiththalassemiaorsicklecelldisease AT brevardj pb2232trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyoftheerythrocytepyruvatekinaseactivatoretavopivatinpatientswiththalassemiaorsicklecelldisease AT trenorc pb2232trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyoftheerythrocytepyruvatekinaseactivatoretavopivatinpatientswiththalassemiaorsicklecelldisease AT woodk pb2232trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyoftheerythrocytepyruvatekinaseactivatoretavopivatinpatientswiththalassemiaorsicklecelldisease AT sheths pb2232trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyoftheerythrocytepyruvatekinaseactivatoretavopivatinpatientswiththalassemiaorsicklecelldisease |